Helping patients every step of the way

PAH Pathways Interactive Resource Locator

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more »

For your patients taking Ventavis, PAH Pathways can help them every step of the way. Our services include:

Simplified enrollment for expedited access
Valuable reimbursement information and financial support programs
Ongoing I-neb AAD training and support
Online patient management to save you time and paperwork
Extensive education and support for Ventavis.

For enrollment and drug access information for your Ventavis patients, click here.

For more information on Ventavis, visit the Ventavis Web site.

I-neb AAD is a registered trademark of Philips Respironics.

Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.

Important safety information about Ventavis:

In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

Tracleer

Please see full Prescribing Information, including BOXED WARNING and Medication Guide for Tracleer.